文献速递免疫规划

四价登革热减毒活疫苗(TAK-003)与重组九价人乳头瘤病毒疫苗联合接种的免疫原性和安全性

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.
PubMed 文献 · Vaccine · 2025-07-31

在泰国开展的3期开放标签随机多中心试验,纳入9至15岁以下健康参与者,1:1随机分为TAK-003与9vHPV联合接种组和单独9vHPV组。结果显示所有HPV型别总IgG水平比值95%CI上限均小于1.5,非劣效性成立;所有登革热血清型M4血清阳性率≥99.6%;未发现新的安全风险。

要点

  • TAK-003与9vHPV联合接种对全部HPV型别的免疫应答达到非劣效性。
  • M4时全部登革热血清型血清阳性率≥99.6%。
  • 试验未发现新的安全风险,结果支持两种疫苗联合接种。

核心结论

  • 研究结果支持TAK-003与9vHPV疫苗联合接种。

研究设计与样本

  • 3期、开放标签、随机、多中心试验,在泰国开展,纳入9至15岁以下健康参与者。
  • 参与者按1:1随机分为Group 1(9vHPV+TAK-003第0月、TAK-003第3月、9vHPV第6月)或Group 2(9vHPV第0月和第6月),末次接种后随访6个月。
  • 主要目标为第7月(末次9vHPV剂量后1个月)TAK-003与9vHPV联合接种对比单独9vHPV的免疫应答非劣效性(HPV总IgG水平比值95%CI上限<1.5)。
  • 614名参与者中606名(98.7%)完成试验,477名(77.7%)纳入符合方案集(PPS)(Group 1=242;Group 2=235)。
  • 安全性分析纳入所有至少接种一剂疫苗的参与者。

主要发现

  • 第7月Group 1各HPV型别总IgG水平为504至7778 mMU/mL,Group 2为561至7823 mMU/mL,全部HPV型别非劣效性成立。
  • 第4月全部登革热血清型血清阳性率≥99.6%。
  • 本试验未发现新的安全风险。

关键数值与推荐

  • 非劣效性标准:HPV总IgG水平比值95%CI上限<1.5。
  • 第7月Group 1各HPV型别总IgG水平504至7778 mMU/mL,Group 2为561至7823 mMU/mL。
  • 第4月全部登革热血清型血清阳性率≥99.6%。

临床怎么用

  • 原文结论为这些发现支持TAK-003与9vHPV疫苗联合接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The tetravalent dengue vaccine TAK-003 and the 9-valent human papillomavirus (9vHPV) vaccine regimens are potentially compatible, with overlapping target age groups, facilitating inclusion of TAK-003 into established immunization programs. METHODS: This phase 3, open-label, randomized, multicenter trial was conducted in Thailand to investigate the immunogenicity and safety of co-administration of TAK-003 with 9vHPV in healthy participants aged ≥9 to <15 years. Participants were randomized 1:1 to either Group 1 (9vHPV + TAK-003 Month [M]0, TAK-003 M3, 9vHPV M6) or Group 2 (9vHPV M0 and M6) and followed up for 6 months after last vaccination. The primary objective was non-inferiority (NI) (upper bound of the 95 % confidence intervals for the HPV total immunoglobulin G (IgG) level ratio < 1.5) of the immune response to 9vHPV co-administered with TAK-003 versus 9vHPV alone at M7 (1 month after the last 9vHPV dose). Safety was assessed for all participants who received at least one vaccine dose. RESULTS: The trial was completed by 606/614 (98.7 %) participants and 477/614 (77.7 %) participants were included in the per-protocol set (PPS) (Group 1 = 242; Group 2 = 235). Total HPV IgG levels for HPV types ranged from 504 to 7778 mMU/mL in Group 1 and 561-7823 mMU/mL in Group 2 at M7 and NI was demonstrated for all HPV types. Seropositivity rates at M4 were ≥ 99.6 % for all dengue serotypes. No new safety risks were identified from this trial. CONCLUSIONS: These findings support the co-administration of the TAK-003 and 9vHPV vaccines. CLINICALTRIALS: gov registration number: NCT04313244.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. El Hindi T, Anugulruengkitt S, Lapphra K, et al. Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine. Vaccine. 2025. PMID: 40749348. doi:10.1016/j.vaccine.2025.127558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。